Skip to content

Drug Eluting Balloon in Peripheral Intervention for In-Stent Restenosis

Drug Eluting Balloon in peripherAl inTErvention for In-Stent Restenosis: the DEBATE-ISR Study

Status
Suspended
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01558531
Acronym
DEBATE-ISR
Enrollment
44
Registered
2012-03-20
Start date
2010-01-31
Completion date
Unknown
Last updated
2015-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Arterial Disease

Keywords

peripheral arterial disease, drug-eluting balloon, restenosis

Brief summary

The purpose of this study is to evaluate the efficacy of drug-eluting balloon angioplasty followed versus conventional balloon angioplasty in superficial femoral artery and popliteal artery re-stenosis.

Interventions

DEVICEDEB

paclitaxel-eluting balloon angioplasty

DEVICEPOBA

conventional balloon angioplasty

Sponsors

Leonardo Bolognese, MD
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age\>18 years * intermittent claudication (Fontane III or IV) * angiographic stenosis\>50% or occlusion of superficial femoral-popliteal artery\>40mm, previously treated with nitinol stent implantation, with at least one below-knee vessel to the ankle

Exclusion criteria

* allergy to Paclitaxel * contraindication for combined antiplatelet treatment * life expectancy \<1 year * hypersensitivity or contraindication to one of the study drugs * lack of consent * need for amputation * angiographic evidence of stent fracture

Design outcomes

Primary

MeasureTime frameDescription
angiographic binary re-restenosis12 monthsincidence of angiographic binary re-restenosis

Secondary

MeasureTime frameDescription
major amputation24 monthsincidence of major amputation
stent thrombosis24 monthsincidence of stent thrombosis
target lesion revascularization24 monthsincidence of target lesion revascularization

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026